Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141113 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).
A Phase 4 study of Adult Attention Deficit Hyperactivity Disorder, sponsored by Rochester Center for Behavioral Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02141113: Completed Phase 4 study of Adult Attention Deficit Hyperactivity Disorder, sponsored by Rochester Center for Behavioral Medicine.
NCT02141113 is a Phase 4 study of Adult Attention Deficit Hyperactivity Disorder that has completed, run by Rochester Center for Behavioral Medicine. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141113, a Phase 4 study of Adult Attention Deficit Hyperactivity Disorder, has completed, sponsored by Rochester Center for Behavioral Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride. The hypothesis is that this medication could be used in adults with Attention Deficit/Hyperactivity Disorder who have not received satisfactory results with their current stimulant ADHD medication. The study drug is investigational for use in adults. Investigational means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in adults.
Primary Outcome
The ADHD-RS is an 18-item scale based on DSM-IV criteria for ADHD. Each item is rated using a likert scale from 0 (none) to 3 (severe), with a total score range of 0-54, with higher scores indicating more symptoms/severity. In this study, we compared the mean change in ADHD-RS total score from baseline to endpoint of the study.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Guanfacine Hydrochloride
Study Locations (1)
Michigan
- Rochester Center for Behavioral Medicine - Rochester Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
What the finished NCT02141113 record still lists
NCT02141113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Adult Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02141113 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02141113 about?
NCT02141113 is a clinical study titled "Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).". This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride....
What is the current status of trial NCT02141113?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2012-11. Estimated completion is 2014-11.
What conditions does trial NCT02141113 study?
This clinical trial studies the following conditions: Adult Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT02141113?
The interventions under investigation include: Placebo (OTHER), Guanfacine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02141113?
This trial is sponsored by Rochester Center for Behavioral Medicine, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141113 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02141113's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia